SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, Honeycomb777, ML33027, stockinvestor56, jump3mb
Search This Board:
Last Post: 10/27/2016 1:24:50 PM - Followers: 90 - Board type: Free - Posts Today: 8
shareholders, please consider purchasing some product(s)

***  ALERT ***

Waiting For FDA Approval Of Fluticare Q3/Q4 2016

Approval of Fluticare could be a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of Fluticare!!

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI)

where he helped move the company's stock price from

19 Cents to $6.00 !!

(Uplisted from OTC to NASDAQ)


Company Profile

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Robert E. Hoffman
Executive Vice President and Chief Financial Officer

Mr. Hoffman was appointed as our Executive Vice President and Chief Financial Officer on September 6, 2016. Prior to Innovus Pharma, Mr. Hoffman was Chief Financial Officer of AnaptysBio, Inc., a clinical stage biopharmaceutical company. He was part of the founding management team of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), a biopharmaceutical company, in 1997, serving as Senior Vice President, Finance and Chief Financial Officer until 2015. He also served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company, from March 2011 to August 2011. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company, Kura Oncology, Inc. (NASDAQ:KURA), a biotechnology company, and MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX), a biopharmaceutical company. He also was a member of the Financial Accounting Standards Board’s Small Business Advisory Committee until 2015 and is a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman received his B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.


Who are the major players at Innovus Pharma?


Share Structure

Shares Outstanding :     ~ 104 Million (as of 10/5/16)   Dr. Damaj owns $23.2M shares alone

- Current cash on-hand is enough to fund operations through Q3 of 2017.  Profitability expected at that time !
- 2017 Projected Revenue of $15M, which would be approximately 3x GREATER than 2016. 

 Company Videos

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation April 2016


Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments



Where can INNV products be seen?


Existing Product Line At Innovus Pharma


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
INNV News: Proxy Statement (definitive) (def 14a) 10/25/2016 01:37:04 PM
INNV News: Current Report Filing (8-k) 10/17/2016 02:51:41 PM
INNV News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 10/11/2016 05:29:49 PM
INNV News: Current Report Filing (8-k) 09/09/2016 06:08:13 AM
INNV News: Initial Statement of Beneficial Ownership (3) 09/07/2016 04:27:11 PM
#3528  Sticky Note MOD: Please sticky. August 2016 Corporate Prsentation pennypincher156 09/20/16 10:21:15 PM
#2422  Sticky Note For anyone willing/wondering about how they can HELP Honeycomb777 08/13/16 11:27:51 AM
#4023   Nothing really to comment on. I have enough ShawnP123 10/27/16 01:24:50 PM
#4022   Not much of a chart guy but don't Honeycomb777 10/27/16 12:29:35 PM
#4020   ShawnP123, entry now don't be late. It's dollar mike007 10/27/16 11:10:31 AM
#4019   Volume = 0. haha mike007 10/27/16 09:55:01 AM
#4018   Definitely not looking for a p and d jump3mb 10/27/16 09:30:12 AM
#4017   Couple of basic reminders .... Do not set Honeycomb777 10/27/16 08:55:14 AM
#4016   I'm in the same boat...! I'm still Bill_gates383 10/27/16 08:09:27 AM
#4015   thanks for advice, but i didn't asked for mike007 10/26/16 04:44:10 PM
#4014   I have to say, this is one of BirdLaw924 10/26/16 04:33:22 PM
#4013   Love it ! lets go INNV mike007 10/26/16 12:31:48 PM
#4012   Could we have FDA approval on the 9th Honeycomb777 10/26/16 11:28:57 AM
#4011   One would think that a run would be Honeycomb777 10/26/16 11:16:21 AM
#4010   Lots of OTC stocks have 500m to a Honeycomb777 10/26/16 11:04:29 AM
#4009   Okay, I see your point in this... BooDog 10/26/16 10:31:45 AM
#4008   Having that luxury doesn't mean they will use Honeycomb777 10/26/16 09:52:28 AM
#4007   Another idea to help YOUR company in addition Honeycomb777 10/26/16 09:44:52 AM
#4006   Problem with the interview is "paid for". So ShawnP123 10/26/16 08:23:57 AM
#4005   Why would they more than double (taking into ShawnP123 10/26/16 08:18:27 AM
#4004   Go INNV! mulally 10/26/16 05:40:37 AM
#4003   Umm What happened with avxl ? Did you forget Flying Albatross 10/25/16 10:38:50 PM
#4002   In an interview with CEOCFO Magazine, Innovus Pharma's mike007 10/25/16 05:17:31 PM
#4001   14A is out! statman25 10/25/16 05:00:38 PM
#4000   Sorry to burst your bubble but definitely not jump3mb 10/25/16 02:12:37 PM
#3999   Spoken like a true day trader Peter Lynch 10/25/16 02:06:53 PM
#3998   Only $3.24 from our 52 week low of Batermere 10/25/16 12:04:57 PM
#3997   Definitely agree Peter. I still believe in jump3mb 10/25/16 10:48:11 AM
#3996   day traders are so funny, the lower a Peter Lynch 10/25/16 10:39:48 AM
#3995   The biggest thing I learned from this stock Bill_gates383 10/25/16 01:06:46 AM
#3994   Just making your life easier - if you Honeycomb777 10/24/16 10:22:54 PM
#3993   I sold for a loss. I think jump3mb 10/24/16 04:59:02 PM
#3992   Right there with you. I was hanging on VeryBeary 10/24/16 04:24:10 PM
#3991   I don't know but assume there could be ShawnP123 10/24/16 03:29:33 PM
#3990   Yup I agree, what is the exact date Peter Lynch 10/24/16 02:09:04 PM
#3989   volumes will pick up during the second week ShawnP123 10/24/16 01:13:22 PM
#3988   Had to dump innv for now. Stock jump3mb 10/24/16 12:58:01 PM
#3987   Dont you think that awareness and volume will Honeycomb777 10/24/16 12:31:49 PM
#3986   Can't say. I do know the traders are ShawnP123 10/24/16 12:25:58 PM
#3985   Yes, the traders are really playing with this ShawnP123 10/24/16 12:23:28 PM
#3984   *you're Jimjames 10/24/16 11:46:11 AM
#3983   Can those in the camp that support the Honeycomb777 10/24/16 11:22:15 AM
#3981   Shawn, there is pretty substantial strength at .27. BirdLaw924 10/24/16 11:11:29 AM
#3980   Your still long and a fool? Adrock 10/24/16 11:08:35 AM
#3979   Then what does .27 say? LMAO. Batermere 10/24/16 11:08:11 AM
#3978   Lets go INNV. mike007 10/24/16 11:03:05 AM
#3977   So you are sticking to a 67%+ decline Honeycomb777 10/24/16 10:24:55 AM
#3976   FWIW - I have 7 folks (I absolutely Honeycomb777 10/24/16 10:21:54 AM
#3975   The share price and trend shouldn't be a ShawnP123 10/24/16 10:19:25 AM
#3974 the dumb investors that sold shares this Honeycomb777 10/24/16 10:11:56 AM
#3973   .241 says it all Adrock 10/24/16 10:04:50 AM
#3972   I'm more curious about whether they have a ShawnP123 10/24/16 09:58:53 AM